Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial

Bluejay Diagnostics, Inc.

SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
Enrollment completion expected within 2-3 months, subject to site activity and patient flow.
Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.